Core Viewpoint - Live Oak Bancshares has shown strong stock performance in 2026, with CEO James S. Iii Mahan selling 20,000 shares for approximately $810,000 as part of a pre-planned trading strategy [1][4]. Transaction Summary - The indirect sale involved 20,000 shares with a transaction value of $810,000, based on a weighted average purchase price of $40.49 [2]. - Post-transaction, Mahan retains 6,454,875 shares, indicating that the sale represents only 0.31% of his overall indirect holdings [4]. Company Overview - Live Oak Bancshares is a regional bank holding company based in Wilmington, North Carolina, offering various commercial banking products and services [6]. - The company generates revenue primarily from interest income on loans and deposits, as well as fees from wealth management and investment advisory accounts [6]. Financial Performance - For fiscal year 2025, Live Oak Bancshares reported Q4 revenue of $150.93 million, marking a 61.75% increase year-over-year [9]. - The company has experienced four consecutive quarters of revenue growth, alongside increases in net income and earnings per share [9]. Market Position - Live Oak Bancshares was recognized as the most active SBA 7(a) lender in the U.S. by dollar volume, securing 2,280 loan approvals and providing over $2.8 billion in funding to small businesses in FY 2025 [8]. - Despite recent revenue growth, the company has faced challenges in stock performance over the past two years, with current stock up 18% as of February 21, 2026 [10].

Core Insights - James P. Zallie, President and CEO of Ingredion, reported the sale of 33,597 shares for approximately $4.02 million amid changes in the board of directors [1][2] - The transaction represents 40.11% of Zallie's direct ownership at the time, which is higher than recent historical medians [6] - Zallie's sale was part of a Rule 10b5-1 trading plan, indicating it was pre-planned and not a reaction to market conditions [9] Company Overview - Ingredion is a global supplier of specialty food ingredients, producing starches, sweeteners, corn oil, protein feeds, and other ingredients derived from corn and starch-based materials [8] - The company serves various sectors including food and beverage manufacturers, animal nutrition producers, and industrial clients across multiple regions [8] Financial Performance - For the trailing twelve months (TTM), Ingredion reported revenue of $7.22 billion and net income of $729 million [4] - The company has a dividend yield of 2.98% and experienced a 1-year price change of -4.23% as of February 11, 2026 [4] - The company's market capitalization stands at $7.4 billion, with a gross margin of 25.97% [7] Recent Developments - Zallie was appointed Chairman of the Board following the resignation of former Chair Gregory Kenny, a common practice in corporate governance [9] - Despite growth in net income and earnings-per-share (EPS) year-over-year, the company reported a decline in revenue and has faced three consecutive quarters of declining net income and EPS [10] - The company is still recovering from global production impacts, which may be a point of concern for investors [10]

Core Insights - The CEO of Novanta, Matthijs Glastra, sold 6,500 shares as part of a Rule 10b5-1 trading plan, which is designed to prevent insider trading accusations [9] - The sale occurred at a time when Novanta's stock price has increased by approximately 23% year-to-date, reflecting strong business performance and demand for its products [10][11] Transaction Summary - The transaction involved the sale of 6,500 shares valued at approximately $878,458.68, based on a weighted average purchase price of $135.15 [2] - Post-transaction, the CEO holds 64,867 shares directly and 54,382 shares indirectly, with a total direct ownership value of around $8.7 million [2][6] Company Overview - Novanta specializes in photonics, vision, and precision motion solutions, primarily serving OEM customers in medical and industrial markets [7][8] - The company reported a total revenue of $960.31 million and a net income of $52.82 million for the trailing twelve months [4] Market Performance - The stock price of Novanta experienced a 1-year change of -3.37%, but has shown significant growth in early 2026 [4][10] - The company's bookings grew by 17% year-over-year, indicating strong demand and contributing to the rising stock price [11]

Core Insights - Robert C. Murphy, Chief Technology Officer of Snap, sold 2 million shares for approximately $10.63 million, as reported in a SEC Form 4 filing [1][2] Transaction Summary - Total shares sold directly: 2,000,000 [2] - Total shares gifted directly: 601,453 [2] - Total shares traded directly: 2,601,453 [2] - Total transaction value: ~$10.6 million [2] - Post-transaction direct shares: 49,012,324 [2] - Post-transaction indirect shares: 10,307,526 [2] - Post-transaction value of direct ownership: ~$256.3 million [2] Company Overview - Snap's total revenue (TTM): $5.93 billion [4] - Snap's net loss (TTM): -$460.49 million [4] - Total employees: 5,061 [4] - 1-year price change (as of Feb. 14, 2026): -54.99% [4] Company Snapshot - Snap operates as a global social media and digital advertising company, focusing on camera-based communication and augmented reality experiences for younger demographics [5] Financial Performance - Snap reduced its net loss year-over-year to $532 million in Q4 FY2025 from $787 million the previous year [7] - Annual net loss decreased from $698 million last year to $460 million in FY2025 [7] Insider Trading Insights - The 2 million shares sold by Murphy are double his historical median of 1 million shares per transaction [8] - Post-transaction, Murphy retains 49,012,324 shares directly and 10,307,526 shares indirectly, with remaining direct holdings valued at approximately $256.3 million [8] Revenue Expectations - Snap expects Q1 2026 revenue to be between $1.50 to $1.53 billion, below the $1.55 billion forecast from analysts, citing increased competition from Meta and TikTok [9]

Core Viewpoint - Qualys is a prominent provider of cloud-based cybersecurity and compliance solutions, with significant revenue and market capitalization, leveraging a subscription-driven SaaS model to deliver essential security tools across various industries [1]. Company Overview - Qualys reported a trailing twelve months (TTM) revenue of $669.125 million and a market capitalization of $4 billion as of February 4, 2026 [1]. - The company serves a diverse customer base, including enterprises, government entities, and small to medium-sized businesses (SMBs) across sectors such as financial services, healthcare, manufacturing, and technology [2]. Product Offerings - Qualys offers a comprehensive suite of cloud-based IT, security, and compliance solutions, including vulnerability management, threat protection, patch management, and asset inventory tools [3]. Recent Transactions - CFO Joo Mi Kim sold 6,799 shares for approximately $873,369.30 on February 4, 2026, which was part of a Rule 10b5-1 trading plan adopted in August 2025 [5][7]. - The sale accounted for 7.14% of direct holdings, significantly higher than the recent median of 1.05%, indicating a reduction in available shares [4]. Market Reaction - Following the stock sale, Qualys announced its fourth quarter and full-year results for 2025, leading to a decline in stock price to a 52-week low of $107.17 on February 9, 2026, due to Wall Street's disappointment over the 2026 revenue guidance [8][9]. - The company projected 2026 sales between $717 million and $725 million, reflecting a growth rate of 7% to 8% over 2025, which is lower than the 10% growth experienced in 2025 [9]. Valuation Insights - Qualys shares are currently trading at a price-to-earnings ratio of 20, marking a low point in recent years, which may present a potential buying opportunity for investors [10].

Group 1 - Maze Therapeutics' Senior Vice President of Finance, Amy Bachrodt, sold 5,000 shares for approximately $227,612 on January 22, 2026, following a strong performance of the company's stock [1][2] - The company has seen a remarkable 1-year price change of 172.38%, with a significant increase of 158% in 2025 after its IPO on January 31, 2025 [4][6] - Following the transaction, Bachrodt's direct ownership decreased to 12,965 shares, representing 0.0269% of the company's outstanding shares [8] Group 2 - Maze Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for renal, cardiovascular, and metabolic diseases, including obesity [5] - The company is advancing to later clinical stages for its medicines targeting kidney and metabolic diseases, which are expected to generate significant revenue upon trial completion [9] - The stock has shown consistent gains for nine months post-IPO, but investors should be cautious of potential short-term drawdowns due to the sustained high buying power [6][7]

Company Overview - Applied Optoelectronics, Inc. is a leading provider of advanced fiber-optic networking products, focusing on high-speed and high-capacity data transmission solutions for clients including data centers, cable television networks, and internet and utility service providers in the U.S., China, and Taiwan [5] - The company's current stock price is $43.61, with a market capitalization of $2.98 billion and a revenue of $421.71 million for the trailing twelve months (TTM) [4] - The stock has experienced a one-year price change of 64.38% as of January 31, 2026 [4] Recent Transaction - David C Kuo, Senior Vice President and Chief Legal Officer, sold 12,000 shares for approximately $540,660 on January 28, 2026, as reported in an SEC Form 4 filing [1][2] - Post-transaction, Kuo holds 114,636 shares, which represents 0.17% of the total shares outstanding [7] - The sale was part of a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not a discretionary sale [6] Financial Performance and Concerns - Despite a 20% increase in share prices in January 2026, the stock had a disappointing performance in 2025, falling around 4% for the entire year [6] - The company has faced negative net losses since 2019, attributed to high operating costs and challenges in implementing fiber solutions, particularly in rural areas [8] - Investors are advised to monitor the company's operational struggles, as consistent negative margins raise concerns [9]

Company Overview - CareDx is a healthcare diagnostics company that specializes in advanced molecular and digital solutions for transplant patient care, focusing on organ and stem cell transplant monitoring [1] - The company generates revenue through direct sales and third-party distribution of proprietary diagnostic tests, software platforms, and related services [2] Recent Transactions - John Hanna, President and CEO of CareDx, sold 19,480 shares in multiple open-market transactions on January 21 and 22, 2026, with an aggregate transaction value of approximately $412,200 [7] - This sale was part of a Rule 10b5-1 trading plan, which allows insiders to buy and sell shares at predetermined times to avoid the appearance of insider trading [8] Insider Ownership - The transaction reduced direct holdings by 3.16%, leaving John Hanna with 597,405 directly held shares, which still represents a substantial ownership position post-sale [5] - The sale of 19,480 shares was the largest among two recent sell-only trades by John Hanna, surpassing the prior transaction of 10,156 shares [6] Financial Performance - CareDx's stock is down 9.36% over the last year and 75.4% since January 22, 2021, but its financial results and future outlook appear promising [9] - The company announced preliminary fourth-quarter revenue of approximately $108 million, an increase of 25% year over year, and full-year revenue of approximately $380 million, an increase of 14% year over year [9] - CareDx repurchased 5.8 million shares for $88 million at an average price of $15.16 per share, indicating strong cash-flow management [9] Strategic Initiatives - CareDx announced a strategic collaboration with 10x Genomics to establish a research initiative called ImmuneScape, which will study the biology of transplant organ rejection and support clinical diagnostic development [10]

Company Overview - Knowles Corporation is a leading provider of advanced micro-acoustic, audio processing, and precision device solutions, employing approximately 5,500 people globally. The company focuses on innovation and direct engagement with OEMs and contract manufacturers, leveraging a broad product offering across high-growth technology sectors [1]. Financial Performance - Knowles reported a 7% year-over-year increase in revenue for the third quarter, totaling $153 million, which was at the high end of its guidance range. Earnings per share (EPS) increased by 22% year over year to $0.33, also at the high end of the guidance range. The company effectively managed cash flow by reducing outstanding bank borrowings by $15 million and repurchasing $20 million worth of shares [7]. Insider Trading Activity - On January 15, 2026, President & CEO Jeffrey Niew sold 50,000 shares of Knowles Corporation for approximately $1,237,500, executed under a Rule 10b5-1 trading plan. This sale represented 5.62% of Niew's direct holdings, marking the largest single open-market sale since December 2024 [5][4][6]. Market Position and Outlook - Ariel Investments highlighted Knowles in its Ariel Mid Cap Value Strategy investor letter, indicating that the company is well-positioned to benefit from its focus on niche, market-leading positions in hearing health and precision devices. Knowles is set to release its fourth-quarter and full-year 2025 results on February 5 [8].

Company Overview - Intuitive Machines is a Houston-based aerospace company focused on providing advanced lunar and orbital solutions for the space industry, supporting robotic and human exploration of the Moon and beyond [8] - The company offers services related to lunar access, orbital services, and lunar data through its various business units, positioning itself as a key enabler of sustained lunar exploration [7][8] - As of January 8, 2026, the company has a market capitalization of $3.07 billion, with a revenue of $218.49 million and a net income of -$193.22 million [4] Recent Insider Transaction - On January 8, 2026, CEO Stephen J. Altemus executed an option exercise and immediate sale of 12,669 shares for a total transaction value of approximately $253,400 [1][2] - The shares sold represented just 0.09% of Altemus's direct ownership, leaving his stake essentially unchanged at over 13.8 million shares [6] - The transaction was part of a Rule 10b5-1 trading plan adopted by Altemus in December 2024, indicating it was not based on insider information [9][10] Market Performance - The sale occurred when Intuitive Machines' stock was on an upswing, reaching a 52-week high of $24.95 on January 24, 2026, due to new customer contracts and the acquisition of Lanteris Space Systems [11] - The company's price-to-sales ratio rose to nearly 11, suggesting that while the stock price has increased, it may be a good time to sell rather than buy [11]